US 11,919,900 B1
1-substituted benzoyl-4-bromopyrrolo[1,2-a]quinoline-3-carboxylate derivatives as antitubercular agents
Katharigatta N. Venugopala, Al-Ahsa (SA); Pran Kishore Deb, Amman (JO); Melendran Pillay, Durban (SA); Sandeep Chandrashekharappa, Raebareli (IN); Mohamed A. Morsy, Al-Ahsa (SA); Bandar E. Aldhubiab, Al-Ahsa (SA); Mahesh Attimarad, Al-Ahsa (SA); Anroop B. Nair, Al-Ahsa (SA); Nagaraja Sreeharsha, Al-Ahsa (SA); Vijaykumar Uppar, Al-Ahsa (IN); Raghu Prasad Mailavaram, Dhule (IN); and Basavaraj Padmashali, Belagavi (IN)
Assigned to KING FAISAL UNIVERSITY, Al-Ahsa (SA)
Filed by KING FAISAL UNIVERSITY, Al-Ahsa (SA)
Filed on Aug. 21, 2023, as Appl. No. 18/236,237.
Int. Cl. C07D 471/04 (2006.01); A61P 31/06 (2006.01)
CPC C07D 471/04 (2013.01) [A61P 31/06 (2018.01)] 17 Claims
 
1. A method of treating tuberculosis selected from the group consisting of multi drug resistant (MDR) strains of Mycobacterium tuberculosis, extensively drug resistant (XDR) strains of Mycobacterium tuberculosis, H37Rv strains of Mycobacterium tuberculosis, and a combination thereof in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of a compound having the formula I:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt, ester, stereoisomer, or solvate thereof, wherein:
R1 is selected from the group consisting of hydrogen, halogen, —CN, —NO2, and methoxy;
R2 is —COOCH3 or —COOC2H5; and
R3 is hydrogen or —COOCH3.